Skip to main content
SpringerLink
Log in

Cognitive and Behavioral Approaches for Treating Substance Use Disorders Among Behavioral Medicine Patients

  • Chapter
  • First Online:
The Massachusetts General Hospital Handbook of Behavioral Medicine

Part of the book series: Current Clinical Psychiatry ((CCPSY))

Abstract

Substance use and substance use disorders (SUD), including alcohol, are a serious public health concern. SUD presentation in clinical practice is highly heterogeneous and can be challenging to treat. Potentially complicating SUD treatment is the co-occurrence of a chronic medical condition. To illustrate these complications and how to address them effectively using cognitive–behavioral interventions, this chapter is divided into six sections: (1) the prevalence, clinical presentations, and complications of having a comorbid alcohol or other substance use disorder across five common medical conditions; (2) description of cognitive and behavioral approaches to addressing alcohol and other drug use disorders in medical settings; (3) a brief overview of the empirical support for CBT approaches for alcohol and other substance use disorders; (4) implementation of CBT in addressing these clinical challenges; (5) reducing harm caused by substances when abstinence is clinically unfeasible; and (6) a case example that highlights CBT principles and techniques in practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in heroin overdose deaths—28 states, 2010 to 2012. MMWR Morb Mortal Wkly Rep. 2014;63:849–54.

    PubMed  Google Scholar 

  2. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on Drug-Related Emergency Department Visits, Rockville; 2013.

    Google Scholar 

  3. Passik SD, Portenoy RK, Ricketts PI. Substance abuse issues in cancer patients. Part 1: prevalence and diagnosis. Oncology (Williston Park). 1998;12:517–21, 524.

    CAS  Google Scholar 

  4. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103:1457–67.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Azar MM, Springer SA, Meyer JP, et al. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Barve S, Kapoor R, Moghe A, et al. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res Health. 2010;33:229–36.

    PubMed  PubMed Central  Google Scholar 

  7. Baum MK, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93–9.

    Article  PubMed  Google Scholar 

  8. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124–33.

    Article  CAS  PubMed  Google Scholar 

  9. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43:411–7.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–9.

    Article  CAS  PubMed  Google Scholar 

  11. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767–74.

    Article  PubMed  Google Scholar 

  12. Miguez MJ, Shor-Posner G, Morales G, et al. HIV treatment in drug abusers: impact of alcohol use. Addict Biol. 2003;8:33–7.

    Article  PubMed  Google Scholar 

  13. Parker GB, Hegarty B, Paterson A, et al. Predictors of post-natal depression are shaped distinctly by the measure of “depression”. J Affect Disord. 2015;173:239–44.

    Article  PubMed  Google Scholar 

  14. Petry NM. Alcohol use in HIV patients: what we don’t know may hurt us. Int J STD AIDS. 1999;10:561–70.

    Article  CAS  PubMed  Google Scholar 

  15. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16:352–8.

    Article  CAS  PubMed  Google Scholar 

  16. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33:126–33.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Maeda M, Nagawa H, Maeda T, et al. Alcohol consumption enhances liver metastasis in colorectal carcinoma patients. Cancer. 1998;83:1483–8.

    Article  CAS  PubMed  Google Scholar 

  18. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J Am Med Assoc. 2000;284:450–6.

    Article  CAS  Google Scholar 

  19. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914–9.

    Article  CAS  PubMed  Google Scholar 

  20. Ostapowicz G, Watson KJ, Locarnini SA, et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730–5.

    Article  CAS  PubMed  Google Scholar 

  21. Schiff ER. Hepatitis C, and alcohol. Hepatology. 1997;26:39S–42S.

    Article  CAS  PubMed  Google Scholar 

  22. Araújo RF, Lira GA, Guedes HG, et al. Lifestyle and family history influence cancer prognosis in Brazilian individuals. Pathol Res Pract. 2013;209:753–7.

    Article  PubMed  Google Scholar 

  23. Schuckit MA. An overview of genetic influences in alcoholism. J Subst Abuse Treat. 2009;36:S5–14.

    PubMed  Google Scholar 

  24. Urbanoski KA, Kelly JF. Understanding genetic risk for substance use and addiction: a guide for non-geneticists. Clin Psychol Rev. 2012;32:60–70.

    Article  PubMed  Google Scholar 

  25. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville: Substance Abuse and Mental Health Services Administration; 2014.

    Google Scholar 

  26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, vol. 5. Washington, DC: Author; 2013.

    Book  Google Scholar 

  27. Bagnardi V, Blangiardo M, La Vecchia C, et al. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2000;25:263–70.

    Google Scholar 

  28. Bagnardi V, Blangiardo M, Vecchia CL, et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85:1700–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rehm J, Room R, Graham K, et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction. 2003;98:1209–28.

    Article  PubMed  Google Scholar 

  30. Bruera E, Moyano J, Seifert L, et al. The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage. 1995;10:599–603.

    Article  CAS  PubMed  Google Scholar 

  31. Dev R, Parsons HA, Palla S, et al. Undocumented alcoholism and its correlation with tobacco and illegal drug use in advanced cancer patients. Cancer. 2011;117:4551–6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Jenkins CA, Schulz M, Hanson J, et al. Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage. 2000;19:174–84.

    Article  CAS  PubMed  Google Scholar 

  33. Parsons HA, Delgado-Guay MO, El Osta B, et al. Alcoholism screening in patients with advanced cancer: impact on symptom burden and opioid use. J Palliat Med. 2008;11:964–8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Neuenschwander AU, Pedersen JH, Krasnik M, et al. Impaired postoperative outcome in chronic alcohol abusers after curative resection for lung cancer. Eur J Cardiothorac Surg. 2002;22:287–91.

    Article  CAS  PubMed  Google Scholar 

  35. Paull DE, Updyke GM, Baumann MA, et al. Alcohol abuse predicts progression of disease and death in patients with lung cancer. Ann Thorac Surg. 2005;80:1033–9.

    Article  PubMed  Google Scholar 

  36. Paull DE, Updyke GM, Davis CA, et al. Complications and long-term survival for alcoholic patients with resectable lung cancer. Am J Surg. 2004;188:553–9.

    Article  PubMed  Google Scholar 

  37. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. 1995;332:1245–50.

    Article  CAS  PubMed  Google Scholar 

  38. Harris HR, Bergkvist L, Wolk A. Alcohol intake and mortality among women with invasive breast cancer. Br J Cancer. 2012;106:592–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jain MG, Ferrenc RG, Rehm JT, et al. Alcohol and breast cancer mortality in a cohort study. Breast Cancer Res Treat. 2000;64:201–9.

    Article  CAS  PubMed  Google Scholar 

  40. Kwan ML, Chen WY, Flatt SW, et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomark Prev. 2013;22:32–41.

    Article  CAS  Google Scholar 

  41. Hurcom C, Copello A, Orford J. The family and alcohol: effects of excessive drinking and conceptualizations of spouses over recent decades. Subst Use Misuse. 2000;35:473–502.

    Article  CAS  PubMed  Google Scholar 

  42. Passik SD, Theobald DE. Managing addiction in advanced cancer patients: why bother? J Pain Symptom Manage. 2000;19:229–34.

    Article  CAS  PubMed  Google Scholar 

  43. Rodrigue JR, Park TL. General and illness-specific adjustment to cancer: relationship to marital status and marital quality. J Psychosom Res. 1996;40:29–36.

    Article  CAS  PubMed  Google Scholar 

  44. Centers for Disease Control and Prevention. CDC fact sheet: new HIV infections in the United States; 2012.

    Google Scholar 

  45. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.

    Article  CAS  PubMed  Google Scholar 

  46. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol Drugs. 2002;63:179.

    Article  Google Scholar 

  47. Buchacz K, McFarland W, Kellogg TA, et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS. 2005;19:1423–4.

    Article  PubMed  Google Scholar 

  48. Ostrow DG, Plankey MW, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51:349–55.

    Article  PubMed  Google Scholar 

  49. Plankey MW, Ostrow DG, Stall R, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007;45:85–92.

    Article  CAS  PubMed  Google Scholar 

  50. Baliunas D, Rehm J, Irving H, et al. Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis. Int J Public Health. 2010;55:159–66.

    Article  PubMed  Google Scholar 

  51. Shuper PA, Joharchi N, Irving H, et al. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. AIDS Behav. 2009;13:1021–36.

    Article  PubMed  Google Scholar 

  52. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    Article  CAS  PubMed  Google Scholar 

  53. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719–34.

    Article  PubMed  Google Scholar 

  54. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed April 24, 2014.

  55. Magiorkinis G, Sypsa V, Magiorkinis E, et al. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol. 2013;9:e1002876.

    Article  CAS  PubMed  Google Scholar 

  56. Tortu S, Neaigus A, McMahon J, et al. Hepatitis C among noninjecting drug users: a report. Subst Use Misuse. 2001;36:523–34.

    Article  CAS  PubMed  Google Scholar 

  57. Basseri B, Yamini D, Chee G, et al. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int. 2010;30:1012–8.

    Article  PubMed  Google Scholar 

  58. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol. 2003;36:242–52.

    Article  PubMed  Google Scholar 

  59. Pierson R. Update 2—Abbott hepatitis C drugs bring high cure rates in trial; 2012.

    Google Scholar 

  60. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4:199–208.

    Article  CAS  PubMed  Google Scholar 

  61. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010 trends in prevalence and control of diabetes in the United States. Ann Intern Med. 2014;160:517–25.

    Article  PubMed  Google Scholar 

  62. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.

    Article  CAS  PubMed  Google Scholar 

  63. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med. 2004;140:211–9.

    Article  PubMed  Google Scholar 

  64. Ajani UA, Hennekens CH, Spelsberg A, et al. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med. 2000;160:1025–30.

    Article  CAS  PubMed  Google Scholar 

  65. Koppes LLJ, Dekker JM, Hendriks HFJ, et al. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care. 2005;28:719–25.

    Article  PubMed  Google Scholar 

  66. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Knott CS, Coombs N, Stamatakis E, et al. All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ. 2015;350:h384.

    Article  PubMed  Google Scholar 

  68. Engler PA, Ramsey SE, Stein MD. Brief alcohol intervention among diabetic patients: a pilot study; 2008.

    Google Scholar 

  69. Lee P, Greenfield JR, Campbell LV. Managing young people with Type 1 diabetes in a “rave” new world: metabolic complications of substance abuse in Type 1 diabetes. Diabet Med. 2009;26:328–33.

    Article  CAS  PubMed  Google Scholar 

  70. Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res. 2005;36:300–6.

    Article  PubMed  Google Scholar 

  71. Shield KD, Parry C, Rehm J. Chronic diseases and conditions related to alcohol use. Alcohol Res Curr Rev. 2014;35:155–71.

    Google Scholar 

  72. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–8.

    Article  PubMed  Google Scholar 

  73. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–12.

    Article  PubMed  Google Scholar 

  74. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4:4–25.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Rupp T, Delaney KA. Inadequate analgesia in emergency medicine. Ann Emerg Med. 2004;43:494–503.

    Article  PubMed  Google Scholar 

  76. Manchikanti L, Manchukonda R, Pampati V, et al. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician. 2005;8:257–61.

    PubMed  Google Scholar 

  77. Broekmans S, Dobbels F, Milisen K, et al. Pharmacologic pain treatment in a multidisciplinary pain center: do patients adhere to the prescription of the physician? Clin J Pain. 2010;26:81–6.

    Article  PubMed  Google Scholar 

  78. Fishman SM, Wilsey B, Yang J, et al. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage. 2000;20:293–307.

    Article  CAS  PubMed  Google Scholar 

  79. Lewis ET, Combs A, Trafton JA. Reasons for under-use of prescribed opioid medications by patients in pain. Pain Med. 2010;11:861–71.

    Article  PubMed  Google Scholar 

  80. Helmerhorst GTT, Vranceanu A-M, Vrahas M, et al. Risk factors for continued opioid use one to two months after surgery for musculoskeletal trauma. J Bone Joint Surg Am. 2014;96:495–9.

    Article  PubMed  Google Scholar 

  81. Bandura A. Social learning theory. Englewood Cliffs: Prentice Hall; 1977.

    Google Scholar 

  82. Hendershot CS, Witkiewitz K, George WH, et al. Relapse prevention for addictive behaviors. Subst Abuse Treat Prev Policy. 2011;6:17.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Miller WR, Rollnick S. Motivational interviewing: helping people change. New York: Guilford; 2012.

    Google Scholar 

  84. Dennis ML, Titus JC, White MK, et al. Global appraisal of individual needs: administration guide for the GAIN and related measures. Bloomington: Chestnut Health System; 2003.

    Google Scholar 

  85. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9:199–213.

    Article  CAS  PubMed  Google Scholar 

  86. Weiss RD, Griffin ML, Hufford C. Craving in hospitalized cocaine abusers as a predictor of outcome. Am J Drug Alcohol Abuse. 1995;21:289–301.

    Article  CAS  PubMed  Google Scholar 

  87. Kelly JF, Greene MC. Beyond motivation: initial validation of the commitment to sobriety scale. J Subst Abuse Treat. 2014;46:257–63.

    Article  PubMed  Google Scholar 

  88. Groshkova T, Best D, White W. The assessment of recovery capital: properties and psychometrics of a measure of addiction recovery strengths. Drug Alcohol Rev. 2013;32:187–94.

    Article  PubMed  Google Scholar 

  89. Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.

    Article  PubMed  Google Scholar 

  90. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70:516–27.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–87.

    Article  PubMed  Google Scholar 

  93. Irvin JE, Bowers CA, Dunn ME, et al. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol. 1999;67:563–70.

    Article  CAS  PubMed  Google Scholar 

  94. Curran PJ, Stice E, Chassin L. The relation between adolescent alcohol use and peer alcohol use: a longitudinal random coefficients model. J Consult Clin Psychol. 1997;65:130–40.

    Article  CAS  PubMed  Google Scholar 

  95. Li F, Jr MB, Hops H, et al. The longitudinal influence of peers on the development of alcohol use in late adolescence: a growth mixture analysis. J Behav Med. 2002;25:293–315.

    Article  PubMed  Google Scholar 

  96. Linehan M. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford; 1993.

    Google Scholar 

  97. Najavits LM. Seeking safety: a treatment manual for PTSD and substance abuse. 1st ed. New York: Guilford; 2001.

    Google Scholar 

  98. Marlatt GA. Buddhist philosophy and the treatment of addictive behavior. Cogn Behav Pract. 2002;9:44–50.

    Article  Google Scholar 

  99. Clapp JD, Burke AC. Discriminant analysis of factors differentiating among substance abuse treatment units in their provision of HIV/AIDS harm reduction services. Soc Work Res. 1999;23:69–76.

    Article  Google Scholar 

  100. MacMaster SA. Harm reduction: a new perspective on substance abuse services. Soc Work. 2004;49:356–63.

    Article  PubMed  Google Scholar 

  101. Hunt N, Ashton M, Lenton S, et al. A review of the evidence-base for harm reduction approaches to drug use. London: Forward Thinking on Drugs; 2003.

    Google Scholar 

  102. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737–44.

    Article  CAS  PubMed  Google Scholar 

  103. Larimer ME, Palmer RS, et al. Relapse prevention: an overview of Marlatt’s cognitive-behavioral model. Alcohol Res Health. 1999;23:151–60.

    CAS  PubMed  Google Scholar 

  104. Sampl, S., 1Kadden, R. (2001). Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users: 5 Sessions, Cannabis Youth Treatment Series, Volume 1. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. BKD384

    Google Scholar 

  105. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861. doi:10.1056/NEJMp1302973.

  106. Yehia BR, Schranz AJ, Umscheid CA, et al. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE. 2014;9(7):e101554. doi:10.1371/journal.pone.0101554.

Download references

Author information

Authors and Affiliations

  1. Behavioral Medicine Service, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Allison K. Labbe Ph.D. & Julianne G. Wilner M.A.

  2. Department of Psychiatry, Center for Addiction Medicine, Massachusetts General Hospital, Boston, MA, USA

    Julie Yeterian M.A. & John F. Kelly Ph.D.

  3. Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 60 Staniford Street, Boston, MA, 02114, USA

    John F. Kelly Ph.D.

Authors
  1. Allison K. Labbe Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie Yeterian M.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julianne G. Wilner M.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John F. Kelly Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allison K. Labbe Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Psychiatry Behavioral Medicine Service, Massachusetts General Hospital, Boston, Massachusetts, USA

    Ana-Maria Vranceanu

  2. Dept. of Psychiatric Oncology & Behavior, Massachusetts General Hospital Cancer Ce, Boston, Massachusetts, USA

    Joseph A. Greer

  3. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA

    Steven A. Safren

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Labbe, A.K., Yeterian, J., Wilner, J.G., Kelly, J.F. (2017). Cognitive and Behavioral Approaches for Treating Substance Use Disorders Among Behavioral Medicine Patients. In: Vranceanu, AM., Greer, J., Safren, S. (eds) The Massachusetts General Hospital Handbook of Behavioral Medicine. Current Clinical Psychiatry. Humana Press, Cham. https://doi.org/10.1007/978-3-319-29294-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29294-6_4

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-29292-2

  • Online ISBN: 978-3-319-29294-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation